Tissue Factor-Targeted “O2-Evolving” Nanoparticles for Photodynamic Therapy in Malignant Lymphoma
Vascular-targeted PDT (vPDT) has produced promising results in the treatment of many cancers, including drug-resistant ones, but little is known about its efficacy in lymphoma. Unfortunately, the lack of a specific therapeutic target and a hypoxic microenvironment for lymphoma jeopardizes the effica...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.524712/full |
| _version_ | 1818116143823454208 |
|---|---|
| author | Ziying Li Ziying Li Yanxue Yin Yanxue Yin Weiwei Jin Bo Zhang Bo Zhang Bo Zhang Han Yan Han Yan Heng Mei Heng Mei Huafang Wang Huafang Wang Tao Guo Tao Guo Wei Shi Wei Shi Yu Hu Yu Hu |
| author_facet | Ziying Li Ziying Li Yanxue Yin Yanxue Yin Weiwei Jin Bo Zhang Bo Zhang Bo Zhang Han Yan Han Yan Heng Mei Heng Mei Huafang Wang Huafang Wang Tao Guo Tao Guo Wei Shi Wei Shi Yu Hu Yu Hu |
| author_sort | Ziying Li |
| collection | DOAJ |
| description | Vascular-targeted PDT (vPDT) has produced promising results in the treatment of many cancers, including drug-resistant ones, but little is known about its efficacy in lymphoma. Unfortunately, the lack of a specific therapeutic target and a hypoxic microenvironment for lymphoma jeopardizes the efficacy of vPDT severely. In this study, we designed a lymphoma tissue factor-targeted “O2-evolving” strategy combining PDT with catalase and HMME-encapsulated, EGFP-EGF1-modified PEG-PLGA nanoparticles (CENPs) to boost PDT efficiency; this combination takes advantage of the low oxygen tension of lymphoma. In our results, CENPs accumulated effectively in the vascular lymphoma in vivo and in vitro, and this accumulation increased further with PDT treatment. Per positron emission tomography imaging, combining CENPs with PDT inhibited lymphoma glucose metabolism significantly. The expression of hypoxia-inducible factor (HIF)-1α in the entrapped catalase groups reduced markedly. These data show that the combined administration of PDT and CENPs can prompt tissue factor-cascade-targeted and self-supply of oxygen and that it has a good therapeutic effect on malignant lymphoma. |
| first_indexed | 2024-12-11T04:17:50Z |
| format | Article |
| id | doaj.art-9050cc58e4914e1795f71ff6fa6115be |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-11T04:17:50Z |
| publishDate | 2020-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-9050cc58e4914e1795f71ff6fa6115be2022-12-22T01:21:12ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-11-011010.3389/fonc.2020.524712524712Tissue Factor-Targeted “O2-Evolving” Nanoparticles for Photodynamic Therapy in Malignant LymphomaZiying Li0Ziying Li1Yanxue Yin2Yanxue Yin3Weiwei Jin4Bo Zhang5Bo Zhang6Bo Zhang7Han Yan8Han Yan9Heng Mei10Heng Mei11Huafang Wang12Huafang Wang13Tao Guo14Tao Guo15Wei Shi16Wei Shi17Yu Hu18Yu Hu19Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaTargeted Biotherapy Key Laboratory of Ministry of Education, Wuhan, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaTargeted Biotherapy Key Laboratory of Ministry of Education, Wuhan, ChinaDepartment of Cardiovascular, Optical Valley School District, Hubei Province Academy of Traditional Chinese Medicine, Wuhan, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaTargeted Biotherapy Key Laboratory of Ministry of Education, Wuhan, ChinaDepartment of Systems Biology, National Cancer Institute Comprehensive Cancer Center, Beckman Research Institute, City of Hope, Monrovia, CA, United StatesInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaTargeted Biotherapy Key Laboratory of Ministry of Education, Wuhan, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaTargeted Biotherapy Key Laboratory of Ministry of Education, Wuhan, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaTargeted Biotherapy Key Laboratory of Ministry of Education, Wuhan, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaTargeted Biotherapy Key Laboratory of Ministry of Education, Wuhan, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaTargeted Biotherapy Key Laboratory of Ministry of Education, Wuhan, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaTargeted Biotherapy Key Laboratory of Ministry of Education, Wuhan, ChinaVascular-targeted PDT (vPDT) has produced promising results in the treatment of many cancers, including drug-resistant ones, but little is known about its efficacy in lymphoma. Unfortunately, the lack of a specific therapeutic target and a hypoxic microenvironment for lymphoma jeopardizes the efficacy of vPDT severely. In this study, we designed a lymphoma tissue factor-targeted “O2-evolving” strategy combining PDT with catalase and HMME-encapsulated, EGFP-EGF1-modified PEG-PLGA nanoparticles (CENPs) to boost PDT efficiency; this combination takes advantage of the low oxygen tension of lymphoma. In our results, CENPs accumulated effectively in the vascular lymphoma in vivo and in vitro, and this accumulation increased further with PDT treatment. Per positron emission tomography imaging, combining CENPs with PDT inhibited lymphoma glucose metabolism significantly. The expression of hypoxia-inducible factor (HIF)-1α in the entrapped catalase groups reduced markedly. These data show that the combined administration of PDT and CENPs can prompt tissue factor-cascade-targeted and self-supply of oxygen and that it has a good therapeutic effect on malignant lymphoma.https://www.frontiersin.org/articles/10.3389/fonc.2020.524712/fullcatalasephotodynamic therapytissue factornanoparticlesEGFP-EGF1protein |
| spellingShingle | Ziying Li Ziying Li Yanxue Yin Yanxue Yin Weiwei Jin Bo Zhang Bo Zhang Bo Zhang Han Yan Han Yan Heng Mei Heng Mei Huafang Wang Huafang Wang Tao Guo Tao Guo Wei Shi Wei Shi Yu Hu Yu Hu Tissue Factor-Targeted “O2-Evolving” Nanoparticles for Photodynamic Therapy in Malignant Lymphoma Frontiers in Oncology catalase photodynamic therapy tissue factor nanoparticles EGFP-EGF1protein |
| title | Tissue Factor-Targeted “O2-Evolving” Nanoparticles for Photodynamic Therapy in Malignant Lymphoma |
| title_full | Tissue Factor-Targeted “O2-Evolving” Nanoparticles for Photodynamic Therapy in Malignant Lymphoma |
| title_fullStr | Tissue Factor-Targeted “O2-Evolving” Nanoparticles for Photodynamic Therapy in Malignant Lymphoma |
| title_full_unstemmed | Tissue Factor-Targeted “O2-Evolving” Nanoparticles for Photodynamic Therapy in Malignant Lymphoma |
| title_short | Tissue Factor-Targeted “O2-Evolving” Nanoparticles for Photodynamic Therapy in Malignant Lymphoma |
| title_sort | tissue factor targeted o2 evolving nanoparticles for photodynamic therapy in malignant lymphoma |
| topic | catalase photodynamic therapy tissue factor nanoparticles EGFP-EGF1protein |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2020.524712/full |
| work_keys_str_mv | AT ziyingli tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT ziyingli tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT yanxueyin tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT yanxueyin tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT weiweijin tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT bozhang tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT bozhang tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT bozhang tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT hanyan tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT hanyan tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT hengmei tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT hengmei tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT huafangwang tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT huafangwang tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT taoguo tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT taoguo tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT weishi tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT weishi tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT yuhu tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma AT yuhu tissuefactortargetedo2evolvingnanoparticlesforphotodynamictherapyinmalignantlymphoma |